Certara (NASDAQ:CERT) Announces Earnings Results, Misses Estimates By $0.02 EPS

Certara (NASDAQ:CERT) announced its earnings results on Monday. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02), Briefing.com reports. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The company’s quarterly revenue was up .8% compared to the same quarter last year. During the same quarter last year, the business posted $0.14 EPS. Certara updated its FY 2026 guidance to 0.350-0.410 EPS.

Certara Stock Performance

NASDAQ:CERT opened at $6.31 on Monday. The stock’s 50-day moving average is $6.25 and its 200-day moving average is $8.11. Certara has a 1-year low of $5.19 and a 1-year high of $13.88. The company has a current ratio of 2.05, a quick ratio of 2.05 and a debt-to-equity ratio of 0.27. The stock has a market cap of $967.45 million, a P/E ratio of -631.00 and a beta of 1.53.

Institutional Investors Weigh In On Certara

A number of institutional investors have recently added to or reduced their stakes in CERT. AQR Capital Management LLC bought a new position in shares of Certara during the first quarter valued at $259,000. Goldman Sachs Group Inc. increased its holdings in Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after purchasing an additional 90,724 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after purchasing an additional 35,954 shares during the last quarter. Jane Street Group LLC raised its position in Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Certara by 29.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after buying an additional 21,099 shares during the period. 73.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on CERT shares. Craig Hallum cut Certara from a “buy” rating to a “hold” rating and set a $10.00 price objective for the company. in a report on Friday, February 27th. Barclays restated an “equal weight” rating and issued a $8.00 price target on shares of Certara in a research report on Friday, March 6th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a report on Thursday, February 26th. KeyCorp reduced their target price on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, April 13th. Finally, Wall Street Zen downgraded Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Certara presently has an average rating of “Moderate Buy” and a consensus target price of $10.44.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.